Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24906687 | 0.94 | MEN1 (0.33) | ALDH1A1 | |
| SCHEMBL26030117 | 0.94 | MEN1 (0.33) | ALDH1A1 | |
| SCHEMBL26852355 | 0.91 | TSHR (0.33) | ALDH1A1 | |
| SCHEMBL26502517 | 0.86 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL26028782 | 0.85 | LTA4H (0.37) | ALDH1A1 | |
| SCHEMBL25360824 | 0.84 | NOS3 (0.40) | ALDH1A1 | |
| SCHEMBL24395113 | 0.84 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL25360834 | 0.84 | NOS3 (0.40) | ALDH1A1 | |
| SCHEMBL24401389 | 0.81 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL26016243 | 0.79 | LTA4H (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744897-B2 | Folate receptor targeted nanoparticle drug conjugates and uses thereof | ELUCIDA ONCOLOGY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230263899-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263898-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263899-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | ALDH1A1 1046/4885 |
| US-20230263898-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | ALDH1A1 1046/4885 |
| US-11744897-B2 | Folate receptor targeted nanoparticle drug conjugates and uses thereof | FOLR1, FOLR2, DHFR | ALDH1A1 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.